


CLAIMS


What is claimed is:

1. A compound comprising



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;
wherein Y is an organic acid functional group, or an amide or ester thereof comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group;
A is $-(CH_2)_6-$, *cis* $-CH_2CH=CH-(CH_2)_3-$, or $-CH_2C\equiv C-(CH_2)_3-$, wherein 1 or 2 carbon atoms may be substituted with S or O; or A is $-(CH_2)_m-Ar-(CH_2)_o-$ wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to 4, and wherein one CH₂ may be substituted with S or O; and
D is aryl or heteroaryl.


2. The compound of claim 1 wherein D is phenyl.
3. The compound of claim 2 wherein D is chlorophenyl.
4. The compound of claim 3 wherein D is 3,5-dichlorophenyl.
5. The compound of claim 2 wherein D is unsubstituted phenyl.
6. The compound of claim 1 wherein A is $-(CH_2)_6-$, *cis* $-CH_2CH=CH-(CH_2)_3-$, or $-CH_2C\equiv C-(CH_2)_3-$.
7. The compound of claim 2 comprising



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;


wherein R^3 is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH_2 , OH, CN, NO_2 , or CF_3 ; and n is 0, 1, 2, or 3.

8. The compound of claim 7 comprising




or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein a dashed line indicates the presence or absence of a covalent bond.

9. The compound of claim 2 comprising




or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof; wherein R^3 is independently methyl, ethyl, isopropyl, fluoro, chloro, bromo, methoxy, ethoxy, isopropoxy, NH_2 , OH, CN, NO_2 , or CF_3 ; R^4 is hydroxyhydrocarbyl having from 1 to 10 carbon atoms; and n is 0, 1, 2, or 3.

10. A method comprising administering an effective amount of a compound to a mammal for the treatment or prevention of glaucoma or ocular hypertension, said compound comprising.



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;
wherein Y is an organic acid functional group, or an amide or ester thereof
comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof
comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group;
A is $-(CH_2)_6-$, *cis* $-CH_2CH=CH-(CH_2)_3-$, or $-CH_2C\equiv C-(CH_2)_3-$, wherein 1 or 2
carbon atoms may be substituted with S or O; or A is $-(CH_2)_m-Ar-(CH_2)_o-$
wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to
4, and wherein one CH_2 may be substituted with S or O; and
D is aryl or heteroaryl.

11. A liquid comprising a compound
wherein said liquid is ophthalmically acceptable,
said compound comprising.



or a pharmaceutically acceptable salt or a prodrug or a metabolite thereof;
wherein Y is an organic acid functional group, or an amide or ester thereof
comprising up to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof
comprising up to 12 carbon atoms; or Y is a tetrazolyl functional group;
A is $-(CH_2)_6-$, *cis* $-CH_2CH=CH-(CH_2)_3-$, or $-CH_2C\equiv C-(CH_2)_3-$, wherein 1 or 2
carbon atoms may be substituted with S or O; or A is $-(CH_2)_m-Ar-(CH_2)_o-$
wherein Ar is interarylene or heterointerarylene, the sum of m and o is from 1 to
4, and wherein one CH_2 may be substituted with S or O; and
D is aryl or heteroaryl.

12. A compound comprising a 4-(aryloxymethyl)azetidin-2-one or a 4-
(heteroaryloxymethyl)azetidin-2-one, substituted at the beta lactam nitrogen
with a prostaglandin α chain, wherein said compound is active at a
prostaglandin EP₂ receptor.